INS and Obesity: Recognizing these phenotype-specific patterns of metabolic dysfunction and fibrotic risk is clinically relevant, as they may inform tailored management strategies-prioritizing anti-inflammatory or insulin-sensitizing approaches in ATD-driven MASLD, while focusing on weight reduction and metabolic load in obesity-driven disease.